Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype | NEJM
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont…